Company XTL Biopharmaceuticals Ltd. TEL AVIV STOCK EXCHANGE
Equities
XTLB
IL0010854979
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30/14/30 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 01/99/01 |
Doron Turgeman
CHM | Chairman | 56 | 30/14/30 |
Daphna Paran
CTO | Chief Tech/Sci/R&D Officer | - | 04/16/04 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30/14/30 |
Director/Board Member | 57 | 29/20/29 | |
Director/Board Member | 53 | 01/17/01 | |
Doron Turgeman
CHM | Chairman | 56 | 30/14/30 |
Director/Board Member | 46 | 08/14/08 | |
Director/Board Member | 57 | 01/15/01 | |
Director/Board Member | 63 | 08/14/08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 514,205,799 | 479,737,353 ( 93.30 %) | 0 | 93.30 % |
Company contact information
XTL Biopharmaceuticals Ltd.
26 Ben-Gurion Street
5112001, Ramat Gan
+972 3 611 6600
http://www.xtlbio.comSector
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.90% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |